BNTC: Benitec Biopharma Inc. Stock

by  •  • Comments Off on BNTC: Benitec Biopharma Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) n/a
Enterprise Value ($M) n/a
Book Value ($M) 15.47
Book Value / Share n/a
Price / Book n/a
NCAV ($M) 14.91
NCAV / Share n/a
Price / NCAV n/a

Profitability (mra)
Return on Invested Capital (ROIC) -1.37
Return on Assets (ROA) -2.65
Return on Equity (ROE) -4.63

Liquidity (mrq)
Quick Ratio 3.62
Current Ratio 3.62

Balance Sheet (mrq) ($M)
Current Assets 20.80
Assets 21.35
Liabilities 5.88
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
7 days ago 13G HBM Healthcare Investments (Cayman) Ltd. 9.99
7 days ago 13D Suvretta Capital Management, Llc 19.99 547.10
04-11 13G/A Adage Capital Partners Gp, L.l.c. 9.99 39.81
02-14 13G/A Citadel Advisors Llc 3.60
02-13 13G/A Janus Henderson Group Plc 7.00 -12.50
12-11 13G/A Franklin Resources Inc 22.90 0.00

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-02-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023 ☐ TRANSITION REPOR
2023-11-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPO
2023-09-21 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended June 30, 2023 ☐ Transition Report under Sect
2023-05-15 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT P

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-05-03 13,197 78,230 16.87
2024-05-02 10,503 18,240 57.58
2024-05-01 5,996 10,352 57.92
2024-04-30 21,249 18,174 116.92

(click for more detail)

Similar Companies
BGXX – Bright Green Corporation BIVI – BioVie Inc.
BMRA – Biomerica, Inc. BON – Bon Natural Life Limited
BPTH – Bio-Path Holdings, Inc.


Financial data and stock pages provided by
Fintel.io